| |
| Names | |
|---|---|
| Preferred IUPAC name
4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzene-1-sulfonamide | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.170.774 
|
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C16H13ClFN3O3S | |
| Molar mass | 381.81 g·mol−1 |
| Pharmacology | |
| QM01AH93 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Cimicoxib (UR-8880 trade name Cimalgex) is a nonsteroidal anti-inflammatory drug (NSAID) used in veterinary medicine to treat dogs for pain and inflammation associated with osteoarthritis and for the management of pain and inflammation associated with surgery.[1] It acts as a COX-2 inhibitor.
Reaction of the imine with TosMIC in the presence of potassium carbonate leads to what may be viewed as 2+3 cycloaddition of the nitrogen analogue of a ketene to form the imidazole ring.
|
| |
|---|---|
| pyrazolones / pyrazolidines |
|
| salicylates |
|
| acetic acid derivatives and related substances |
|
| oxicams |
|
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) |
|
| COX-2 inhibitors (coxibs) |
|
| other |
|
| NSAID combinations |
|
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
| |
 | This veterinary medicine–related article is a stub. You can help Wikipedia by expanding it. |
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
